Similarly, a window-of-opportunity trial in early HER2-negative BC showed that hypoxic tumors were less likely to achieve pCR after treatment with neoadjuvant nintedanib, a multi-tyrosine kinase inhibitor [94]. The gene discussed is ERBB2; the disease is breast cancer.